

**Anti-CD19 Reference Antibody (inebilizumab)  
Recombinant Antibody  
Catalog # APR10136****Specification**

---

**Anti-CD19 Reference Antibody (inebilizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P15391</a>
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.5 KDa

**Anti-CD19 Reference Antibody (inebilizumab) - Additional Information****Target/Specificity**  
CD19**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-CD19 Reference Antibody (inebilizumab) - Protein Information****Name** CD19**Function**  
Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes (PubMed:<a href="http://www.uniprot.org/citations/29523808" target="\_blank">29523808</a>). Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:<a href="http://www.uniprot.org/citations/1373518" target="\_blank">1373518</a>, PubMed:<a href="http://www.uniprot.org/citations/16672701" target="\_blank">16672701</a>, PubMed:<a href="http://www.uniprot.org/citations/2463100" target="\_blank">2463100</a>). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores (PubMed:<a href="http://www.uniprot.org/citations/12387743" target="\_blank">12387743</a>, PubMed:<a href="http://www.uniprot.org/citations/16672701" target="\_blank">16672701</a>, PubMed:<a href="http://www.uniprot.org/citations/9317126" target="\_blank">9317126</a>, PubMed:<a href="http://www.uniprot.org/citations/9382888" target="\_blank">9382888</a>). Is not required

for early steps during B cell differentiation in the blood marrow (PubMed:<a href="http://www.uniprot.org/citations/9317126" target="\_blank">9317126</a>). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:<a href="http://www.uniprot.org/citations/1373518" target="\_blank">1373518</a>, PubMed:<a href="http://www.uniprot.org/citations/2463100" target="\_blank">2463100</a>). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:<a href="http://www.uniprot.org/citations/12387743" target="\_blank">12387743</a>, PubMed:<a href="http://www.uniprot.org/citations/16672701" target="\_blank">16672701</a>, PubMed:<a href="http://www.uniprot.org/citations/9317126" target="\_blank">9317126</a>).

**Cellular Location**

Cell membrane; Single-pass type I membrane protein. Membrane raft {ECO:0000250|UniProtKB:P25918}; Single-pass type I membrane protein {ECO:0000250|UniProtKB:P25918}

**Tissue Location**


Detected on marginal zone and germinal center B cells in lymph nodes (PubMed:2463100). Detected on blood B cells (at protein level) (PubMed:16672701, PubMed:2463100)

**Anti-CD19 Reference Antibody (inebilizumab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-CD19 Reference Antibody (inebilizumab) - Images**



Anti-CD19 Reference Antibody (inebilizumab) on SDS-PAGE under reducing (R) condition. The gel

was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CD19 Reference Antibody (inebilizumab) is more than 98.79% ,determined by SEC-HPLC.